Fibrinolysis for patients with intermediate-risk pulmonary embolism

G Meyer, E Vicaut, T Danays, G Agnelli… - … England Journal of …, 2014 - Mass Medical Soc
Background The role of fibrinolytic therapy in patients with intermediate-risk pulmonary
embolism is controversial. Methods In a randomized, double-blind trial, we compared …

Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism

SV Konstantinides, E Vicaut, T Danays… - Journal of the American …, 2017 - jacc.org
Background: The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is
unknown. Objectives: This study investigated the long-term prognosis of patients with …

[HTML][HTML] Reduced-dose intravenous thrombolysis for acute intermediate–high-risk pulmonary embolism: rationale and design of the pulmonary embolism international …

O Sanchez, A Charles-Nelson, W Ageno… - Thrombosis and …, 2022 - thieme-connect.com
Intermediate–high-risk pulmonary embolism (PE) is characterized by right ventricular (RV)
dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic …

[HTML][HTML] Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double‐blind, placebo …

JA Kline, KE Nordenholz, DM Courtney… - Journal of thrombosis …, 2014 - Elsevier
Background Acute pulmonary embolism (PE) can worsen quality of life due to persistent
dyspnea or exercise intolerance. Objective Test if tenecteplase increases the probability of a …

Efficacy of thrombolytic agents in the treatment of pulmonary embolism

T Capstick, MT Henry - European Respiratory Journal, 2005 - Eur Respiratory Soc
Recent guidelines recommend bolus-dose alteplase for treating massive pulmonary
embolism (PE). However, the safest and most effective treatment is as yet unknown. In the …

Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry

S Konstantinides, A Geibel, M Olschewski, F Heinrich… - Circulation, 1997 - Am Heart Assoc
Background Thrombolytic treatment has been shown to accelerate resolution of major
pulmonary embolism and lead to a rapid improvement of right-side hemodynamics …

Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomized trial

SZ Goldhaber, G Agnelli, MN Levine - Chest, 1994 - Elsevier
Study objective To test the hypothesis that a reduced dose of bolus recombinant human
tissue-type plasminogen activator (rt-PA)(0.6 mg/kg/15 min, maximum of 50 mg) would result …

PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2

S Dalla-Volta, A Palla, A Santolicandro… - Journal of the American …, 1992 - Elsevier
Background. The effect of alteplase versus heparin in pulmonary embolism has not been
studied extensively with serial pulmonary angiograms. Objectives. The aim of this …

Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular …

Steering Committee - American heart journal, 2012 - Elsevier
BACKGROUND: In acute pulmonary embolism (PE), overt right ventricular (RV) failure with
cardiogenic shock indicates a poor prognosis. However, normotensive patients with acute …

Fibrinolysis for acute pulmonary embolism

G Piazza, SZ Goldhaber - Vascular Medicine, 2010 - journals.sagepub.com
Acute pulmonary embolism (PE) presents as a constellation of clinical syndromes with a
variety of prognostic implications. Patients with acute PE who have normal systemic arterial …